Addressing a Treatment Gap: Rationale for Increasing the Starting Dose of Simvastatin in Hypercholesterolaemic Patients

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.22, Iss.5, 2002-05, pp. : 291-301

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rationale for Increasing the Starting Dose of Simvastatin

By Lucas B.D. Elhabyan A-K. Lucas K.H.

Clinical Drug Investigation, Vol. 22, Iss. 9, 2002-01 ,pp. : 639-640

Adis International

Access to resources Recommend Favorite

The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients: A Comparison of Atorvastatin, Simvastatin, Lovastatin and Fluvastatin

By McLain R.W.

PharmacoEconomics, Vol. 14, Iss. 1, 1998-07 ,pp. : 59-70

Adis International

Access to resources Recommend Favorite

Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia

By Filippatos Theodosios D Elisaf Moses S

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 12, 2011-08 ,pp. : 1945-1958

Informa Healthcare

Access to resources Recommend Favorite

Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis

By Pereira Michelly Cardoso Pablo Rocha Laurindo Rêgo Moacyr Gonçalves Sayonara Santos Flaviana Galdino-Pitta Marina Dantas Andréa Duarte Ângela Pitta Maira

Inflammation Research, Vol. 63, Iss. 4, 2014-04 ,pp. : 309-315

Springer Publishing Company

Access to resources Recommend Favorite

Rationale for Fixed-Dose Combinations in the Treatment of Hypertension: The Cycle Repeats

By Sica D.A.

Drugs, Vol. 62, Iss. 3, 2002-01 ,pp. : 443-462

Adis International

Access to resources Recommend Favorite